Antiseizure drugs (ASDs) prevent the occurrence of seizures; there is no evidence that they
have disease-modifying properties. In the more than 160 years that orally administered …

Since the N-methyl-D-aspartate receptor (NMDAR) subunits were cloned less than two
decades ago, a substantial amount of research has been invested into understanding their …

In the past decade, nine new drugs have been licensed for the treatment of epilepsy. With
limited clinical experience of these agents, the mechanisms of action of antiepileptic drugs …

There is a remarkable array of new chemical entities in the current antiepileptic drug (AED)
development pipeline. In some cases, the compounds were synthesized in an attempt …

A substantial amount of research has shown that N-methyl-D-aspartate receptors (NMDARs)
may play a key role in the pathophysiology of several neurological diseases, including …

Novel antiepileptic drugs (AEDs) are thought to act on voltage‐sensitive ion channels, on
inhibitory neurotransmission or on excitatory neurotransmission. Two successful examples …

The effect of the new antiepileptic drug levetiracetam (LEV; KEPPRA™) on the neuronal
high-voltage-activated (HVA) Ca2+ current was investigated on pyramidal neurones …

The development of medications used in the treatment of epilepsy has accelerated over the
past decade, and has benefited from a parallel growth in our knowledge of the basic …

In pyramidal cortical cells, high-voltage-activated Ca2− currents affect seizure propagation
and the release of excitatory amino acids at the corticostriatal axon terminals. The new …

Gabapentin (1 (aminomethyl) cyclohexane acetic acid; GBP) is a recently developed
anticonvulsant, for which the mechanism of action remains quite elusive. Besides its …